Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
US9545396B2 · kind B2 · utility
0Cited by
28References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 2013 |
| Grant date | Jan 17, 2017 |
| Priority date | — |
| Expiry date | Sep 29, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/1137
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical composition of PRCP antagonist, PREP antagonist, or PRCP-PREP dual antagonist. The present invention also relates to a pharmaceutical composition jointly using PRCP antagonist and mTOR antagonist, or jointly using PREP antagonist and mTOR antagonist, or jointly using PRCP-PREP dual antagonist and mTOR antagonist. In addition, the present invention also relates to a method for utilizing the pharmaceutical compositions to treat and prevent cancers and diseases related to insulin receptor substrate protein and PI3K/AKT/mTOR signal pathway.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.